Overview

Etoricoxib Prescribing Patterns and Adverse Events of Interest in Primary Care in the United Kingdom (MK-0663-162 AM1)

Status:
Completed
Trial end date:
2015-03-01
Target enrollment:
Participant gender:
Summary
This postmarketing study was conducted to describe prescribing patterns for etoricoxib (ARCOXIA®) in General Practice and describe the incidence of selected adverse events recorded in the United Kingdom (UK) Medicines and Health Care Products Regulatory Agency (MHRA) General Practice Research Database (GPRD).
Details
Lead Sponsor:
Merck Sharp & Dohme Corp.
Treatments:
Etoricoxib